BHVN vs NVO: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
NVO is the larger of the two ($169.20B market cap): the incumbent the market prices for continued execution (10.93x forward earnings, beta 0.37). BHVN is the smaller challenger ($1.94B), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, BHVN fits (beta 3.13). If you want the steadier ride, NVO fits (beta 0.37).
BHVN vs NVO: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BHVN | NVO | What it tells you |
|---|---|---|---|
| Market cap | $1.94B | $169.20B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -8.40 | 10.93 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 3.13 | 0.37 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 48% of range | 11% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how BHVN and NVO affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BHVN and NVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BHVN and NVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Biohaven Ltd (BHVN) do?
Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies across neuroscience, immunology, obesity and oncology. It was created in 2022 when Pfizer acquired the original Biohaven's CGRP migraine business (including Nurtec ODT) for roughly $11.6 billion; the remaining non-CGRP pipeline was spun out into the current publicly traded Biohaven Ltd. Its programs include taldefgrobep alfa (a myostatin-activin pathway inhibitor being tested in obesity and spinal muscular atrophy), troriluzole (VYGLXIA, targeted at spinocerebellar ataxia), opakalim (BHV-7000, a Kv7 ion channel activator for focal epilepsy and depression), MoDE and TRAP extracellular degraders such as BHV-1300 (now in Phase 3 for Graves' disease) and BHV-1400 (IgA nephropathy), and antibody-drug conjugates such as BHV-1530.
What does Novo Nordisk (NVO) do?
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.
BHVN vs NVO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BHVN drivers: Taldefgrobep obesity readout, now in 2027; Opakalim epilepsy and depression, now with a regulatory delay.
- NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Biohaven has no product sales and posts large quarterly net losses (about $129 million in Q3 2026, against an analyst consensus that had expected licensing income to produce a small profit), so it depends on equity financing and licensing deals; equity raises dilute existing shareholders. For NVO, novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and only about 6% in Q3, and the ADR down about 21% over the three months to November 20, 2026.
BHVN or NVO: which should you pick?
If the story you believe is BHVN's (Taldefgrobep obesity readout, now in 2027), BHVN is the more direct way to own it; if it is NVO's (GLP-1 obesity and diabetes demand), NVO is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BHVN and NVO guides.
BHVN vs NVO: the full fundamentals
BHVN. Biohaven trades as a pipeline-value biotech rather than on earnings, with a market cap near $1.9 billion and no product revenue. The quarterly loss has narrowed from about $173 million in Q3 2025 to about $129 million in Q3 2026 as research spending fell, but the licensing income analysts had pencilled into the third quarter did not appear because the Ono payment arrived after quarter end. Consensus now looks for fourth-quarter revenue of about $147 million and EPS of about $0.44 as deal payments are recognized. Cash of about $164 million at the end of September keeps financing and runway front of mind, which is why closing the SK Biopharmaceuticals deal matters.
NVO. Novo Nordisk once commanded a premium pharma multiple on the strength of GLP-1 growth; at about 9.7x trailing and 11x forward earnings in November 2026 it trades at a discount that reflects slowing sales and share loss to Eli Lilly, even after a Q3 beat and a raised outlook. Trailing net income is lifted by an unusually large Q1 2026, which is one reason forward earnings estimates sit below trailing ones. Figures are reported in Danish kroner (market cap and the ADR dividend in dollars) and should be verified against the latest filings; the next report is due February 3, 2027.
Headline figures (approximate, November 2026): BHVN shows market cap ~$1.9B, share price (nov 20, 2026) ~$12.85 (YTD ~+19%, 1y ~+34%), 52-week range ~$8.03 to ~$18.24, q3 2026 net loss ~$129M (EPS -$0.86 vs ~+$0.16 est.); NVO shows revenue (last four quarters) ~DKK 307 billion (+6% YoY in Q3 2026), revenue (2026 consensus) ~DKK 311 billion, net income (ttm) ~DKK 113 billion, gross margin ~83%.
The bottom line: BHVN vs NVO
BHVN and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BHVN and NVO exposure against your real portfolio. It is not an investment adviser.
Wondering how BHVN or NVO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Biohaven Ltd
Ask Walnut's AI anything about BHVN and see how it fits what you own.
FAQ
What is the difference between BHVN and NVO?
+
Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies across neuroscience, immunology, obesity and oncology. Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BHVN or NVO the better stock?
+
Neither is universally better. NVO is the larger incumbent; BHVN is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BHVN or NVO?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BHVN and NVO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BHVN vs NVO?
+
BHVN: Biohaven has no product sales and posts large quarterly net losses (about $129 million in Q3 2026, against an analyst consensus that had expected licensing income to produce a small profit), so it depends on equity financing and licensing deals; equity raises dilute existing shareholders. Cash stood at about $164 million at the end of September 2026 against about $264 million of notes payable, before the $80 million Ono upfront received in October and before the SK Biopharmaceuticals deal, whose $350 million closing payment still depends on remaining conditions. The 2025 Complete Response Letter for troriluzole and the 2026 partial clinical hold on opakalim show regulatory outcomes can go against the company, and the troriluzole decision in early 2027 and several late-stage readouts are binary events that could sharply move the stock in either direction. The obesity field is intensely competitive and dominated by well-capitalized GLP-1 players, taldefgrobep's muscle-sparing thesis is still unproven in humans at scale, and its readout has slipped to 2027. Cash runway relative to a heavy research budget is a persistent concern that investors should monitor. NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and only about 6% in Q3, and the ADR down about 21% over the three months to November 20, 2026. Oral competitors, including Lilly's Foundayo (backed by an EMA panel in October 2026) and Viking's Phase 3 pill, raise the pressure further. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics. Debt has also risen with the capacity build (about DKK 134 billion against about DKK 46 billion of cash at September 30, 2026), and trailing free cash flow of about DKK 33 billion is far below net income.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BHVN or NVO; figures are approximate and dated (as of November 2026). Verify current data before investing.